Table I.
Baseline characteristics
| Characteristic | All | Bronchiectasis | Nonbronchiectasis | P |
|---|---|---|---|---|
| Patients total, n | 108 | 34 | 74 | |
| Age (y) | 47 ± 14.3 | 52 ± 14 | 45 ± 14 | .01∗ |
| Sex: female | 63 (58) | 18 (53) | 45 (61) | .53† |
| BMI (kg/m2) | 28 ± 6 | 27 ± 5 | 29 ± 6 | .13‡ |
| ACQ-5 score | 1.7 (1.0-2.6) | 1.7 (0.8-2.6) | 1.7 (1.0-2.6) | .43‡ |
| Cough and phlegm (preceding 12 mo) | 85 (79) | 30 (88) | 55 (74) | .06† |
| Cough and phlegm for 3 consecutive months (preceding 2 y) | 49 (45) | 20 (59) | 29 (39) | .05† |
| Courses of antibiotics (preceding 12 mo) | 1 (0-2) | 1 (0-3) | 1 (0-2) | .14† |
| Courses of OCSs (preceding 12 mo) | 1 (0-3) | 1 (0-2) | 1 (0-3) | .77‡ |
| Never smokers | 63 (58) | 17 (50) | 46 (62) | .29† |
| Smoking (pack years) | 9 (3-21) | 9 (7-35) | 10 (3-20) | .34‡ |
| Atopy | 56 (52) | 21 (62) | 45 (61) | .21§ |
| Aspergillus positive|| | 11 (10) | 8 (24) | 3 (4) | .004§ |
| Aspergillus positive||and IgE > 1000 IU/mL | 3 (3) | 2 (6) | 1 (1) | .23§ |
| Cumulative ICS dose | 1800 (1600-2400) | 1600 (1600-2400) | 2200 (1600-2400) | .19‡ |
| OCSs for asthma | 15 (14) | 6 (18) | 9 (12) | .55§ |
| Lung function | ||||
| FEV1 % predicted | 75 (21) | 72 (25) | 77 (19) | .37∗ |
| FVC % predicted | 87 (17) | 86 (18) | 87 (16) | .85∗ |
Data are presented as n (%), mean ± SD, or median (IQR).
BMI, Body mass index; FVC, forced vital capacity; ICS, inhaled corticosteroid; IQR, interquartile range; OCS, oral corticosteroid.
∗
Welch ANOVA.
†
χ2 test.
‡
Kruskal-Wallis test.
§
Fisher exact test.
||
Aspergillus positive: positive skin prick test result and/or specific IgE for A fumigatus.